How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Buy
52
DNA Quote, Financials, Valuation and Earnings
Last price:
$10.13
Seasonality move
:
-41.81%
Day range:
$8.65 - $10.23
52-week range:
$5.00 - $17.58
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.06x
P/B ratio:
1.09x
Volume:
2.7M
Avg. volume:
1M
1-year change:
-26.17%
Market cap:
$612M
Revenue:
$227M
EPS (TTM):
-$6.23
Analysts' Opinion
-
Consensus RatingGinkgo Bioworks Holdings, Inc. has received a consensus rating of No Consensus. The company's average rating is a No Consensus based on 1 Buy rating, 0 Hold ratings, and 1 Sell rating.
-
Price Target DownsideAccording to analysts' consensus price target of $10.00, Ginkgo Bioworks Holdings, Inc. has an estimated downside of -0.99% from its current price of $10.10.
-
Price Target UpsideAccording to analysts, the highest upside price target is $12.00 representing -100% upside increase from its current price of $10.10.
Fair Value
-
According to the consensus of 2 analysts, Ginkgo Bioworks Holdings, Inc. has -0.99% downside to fair value with a price target of $10.00 per share.
DNA vs. S&P 500
-
Over the past 5 trading days, Ginkgo Bioworks Holdings, Inc. has overperformed the S&P 500 by 12.71% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Ginkgo Bioworks Holdings, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Ginkgo Bioworks Holdings, Inc. revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Ginkgo Bioworks Holdings, Inc. reported revenues of $38.8M.
Earnings Growth
-
Ginkgo Bioworks Holdings, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Ginkgo Bioworks Holdings, Inc. reported earnings per share of -$1.45.
Enterprise value:
564.2M
EV / Invested capital:
--
Price / LTM sales:
3.06x
EV / EBIT:
--
EV / Revenue:
3.12x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-3.01x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$75M
Return On Assets:
-25.83%
Net Income Margin (TTM):
-188%
Return On Equity:
-50.92%
Return On Invested Capital:
-30.68%
Operating Margin:
-227.14%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $315M | $218M | $180.6M | $89M | $38.8M | |
| Gross Profit | $142.5M | $119.7M | $75M | $59.9M | $11.9M | |
| Operating Income | -$812.3M | -$515.4M | -$344.2M | -$51.6M | -$88.2M | |
| EBITDA | -$697M | -$455.2M | -$283.2M | -$34.5M | -$74M | |
| Diluted EPS | -$17.89 | -$12.90 | -$6.23 | -$1.08 | -$1.45 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.8B | $1.5B | $1.1B | $662.5M | $506.1M | |
| Total Assets | $2.2B | $1.9B | $2B | $1.5B | $1.2B | |
| Current Liabilities | $90.3M | $124.8M | $168.5M | $114.4M | $115.3M | |
| Total Liabilities | $532.6M | $431M | $773.7M | $682.9M | $629.4M | |
| Total Equity | $1.6B | $1.4B | $1.3B | $797.9M | $559.8M | |
| Total Debt | $16.3M | $59.8M | $403.7M | $445.6M | $422.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$342.2M | -$335M | -$165.8M | -$103.5M | -$31.6M | |
| Cash From Investing | -$4.3M | -$95.8M | -$348.5M | -$10.2M | -$72.8M | |
| Cash From Financing | $95.2M | -$2.2M | $9.4M | -$465K | $9.9M | |
| Free Cash Flow | -$405.2M | -$387.3M | -$187.2M | -$118.6M | -$31.6M | |
DNA
Sector
Market Cap
$612M
$23.4M
Price % of 52-Week High
57.45%
48.49%
Dividend Yield
0%
0%
Shareholder Yield
-0.49%
-1.67%
1-Year Price Total Return
-26.17%
-23.18%
Beta (5-Year)
--
0.504
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$9.04
200-day SMA
Sell
Level
$10.32
Bollinger Bands (100)
Sell
Level
8.21 - 12.87
Chaikin Money Flow
Sell
Level
-61.3M
20-day SMA
Buy
Level
$9.44
Relative Strength Index (RSI14)
Buy
Level
57.77
ADX Line
Buy
Level
19.69
Williams %R
Neutral
Level
-29.6736
50-day SMA
Buy
Level
$9.10
MACD (12, 26)
Sell
Level
-0.04
25-day Aroon Oscillator
Sell
Level
-40
On Balance Volume
Sell
Level
-48.4M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-5.9551)
Sell
CA Score
(Annual)
Level (-1.3308)
Buy
Beneish M-Score
(Annual)
Level (-3.2566)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (2.4338)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform enables biotechnology applications across diverse markets, from food, agriculture, industrial chemicals, and pharmaceuticals. It operates through the Cell Engineering and Biosecurity segments. The Cell Engineering segment consists of end-to-end cell engineering solutions and cell engineering tools offerings for biological research and development. The Biosecurity segment focuses on biomonitoring and bioinformatics support services, offered to both government and non-government customers through the company's two core offerings, Canopy and Horizon. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.
Stock Forecast FAQ
In the current month, DNA has received 1 Buy ratings 0 Hold ratings, and 1 Sell ratings. The DNA average analyst price target in the past 3 months is $10.00.
-
Where Will Ginkgo Bioworks Holdings, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Ginkgo Bioworks Holdings, Inc. share price will drop to $10.00 per share over the next 12 months.
-
What Do Analysts Say About Ginkgo Bioworks Holdings, Inc.?
Analysts are divided on their view about Ginkgo Bioworks Holdings, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Ginkgo Bioworks Holdings, Inc. is a Sell and believe this share price will rise from its current level to $9.00.
-
What Is Ginkgo Bioworks Holdings, Inc.'s Price Target?
The price target for Ginkgo Bioworks Holdings, Inc. over the next 1-year time period is forecast to be $10.00 according to 2 Wall Street analysts, 1 of them rates the stock a Buy, 1 rates the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is DNA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Ginkgo Bioworks Holdings, Inc. is a No Consensus. 1 of 2 analysts rates the stock a No Consensus at this time.
-
How Can I Buy Shares Of DNA?
You can purchase shares of Ginkgo Bioworks Holdings, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Ginkgo Bioworks Holdings, Inc. shares.
-
What Is The Ginkgo Bioworks Holdings, Inc. Share Price Today?
Ginkgo Bioworks Holdings, Inc. was last trading at $10.13 per share. This represents the most recent stock quote for Ginkgo Bioworks Holdings, Inc.. Yesterday, Ginkgo Bioworks Holdings, Inc. closed at $10.10 per share.
-
How To Buy Ginkgo Bioworks Holdings, Inc. Stock Online?
In order to purchase Ginkgo Bioworks Holdings, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get DNA Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
DNA
Sector
P/E ratio
--
23.40x
PEG ratio
--
-0.01x
P/B ratio
1.09x
1.74x
Price / LTM sales
3.06x
1.48x
Growth Metrics
DNA
Sector
Revenue growth
-56.39%
3.36%
Earnings growth
-34.39%
9.35%
Revenue (5-year growth)
33.18%
6.22%
Earnings forecast
-$1.11
-$0.19
Profitability
DNA
Sector
Profitability FY 2024
$137.5M
$2.7M
Return on invested capital
-30.68%
-33.62%
Return on assets
-25.83%
-29.68%
Return on equity
-50.92%
-38.98%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Feb
24
Estimated Next Earnings Date
Feb
5
Balance Sheet
DNA
Sector
Total cash
$470.7M
$25M
Short term investments
--
$23.9M
Total assets
$1.4B
$72.5M
Long term debt
$422.9M
$2.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
53
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 30x
Alerts
Sell
40
BILL alert for Feb 7
Bill Holdings, Inc. [BILL] is up 37.11% over the past day.
Buy
75
PRLB alert for Feb 7
Proto Labs, Inc. [PRLB] is up 28.33% over the past day.
Sell
30
MSTR alert for Feb 7
Strategy, Inc. [MSTR] is up 26.08% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
